Toxic epidermal necrolysis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:29 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Toxic epidermal necrolysis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Tildrakizumab for Eye Problems in Patients with Lyell Syndrome https://clinicaltrials.eu/trial/study-of-tildrakizumab-for-eye-problems-in-patients-with-lyell-syndrome/ Wed, 29 Apr 2026 15:08:16 +0000 https://clinicaltrials.eu/trial/study-of-tildrakizumab-for-eye-problems-in-patients-with-lyell-syndrome/ This study looks at Lyell syndrome, a severe skin condition that can lead to long-lasting eye problems even after the initial illness has passed. People who have had Lyell syndrome may continue to experience eye issues such as dryness, irritation, and inflammation of the eye surface, which can affect their vision and daily comfort. The treatment being tested is Ilumetri, which contains the active substance tildrakizumab. This medicine is given as an injection under the skin and works by affecting the immune system to reduce inflammation. The study will use doses up to 200 milligrams per injection, with a total amount of up to 600 milligrams over a treatment period of three months.

The purpose of the study is to see if tildrakizumab can improve the eye problems that remain after Lyell syndrome. The main focus is on measuring how long the tear film stays stable on the eye surface before breaking up, which is an important sign of eye surface health. A longer time means better moisture and less irritation. The study will also look at how patients feel about their eye symptoms and how these problems affect their quality of life and ability to see clearly.

During the study, participants will receive the treatment and attend follow-up visits where doctors will check their eyes and measure changes in tear film stability. Safety will be monitored throughout the study, and participants will be asked about how well they tolerate the treatment and any changes in their symptoms. The study is expected to run from early 2026 until mid-2027.

]]> Treatment with Mesenchymal Stromal Cells for Adults with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS-TEN) Affecting More Than 10% of Body Surface https://clinicaltrials.eu/trial/study-on-the-use-of-allogeneic-adipose-derived-mesenchymal-stromal-cells-for-adults-with-severe-skin-reaction-sjs-ten-affecting-over-10-of-body-surface/ Wed, 29 Apr 2026 15:05:44 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-allogeneic-adipose-derived-mesenchymal-stromal-cells-for-adults-with-severe-skin-reaction-sjs-ten-affecting-over-10-of-body-surface/ This study focuses on patients with Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis (SJS-TEN), a severe skin condition where at least 10% of the body surface area is affected. This rare and serious condition causes the top layer of skin to detach from the lower layers, similar to severe burns. The treatment being investigated uses allogeneic mesenchymal stromal cells, which are specialized cells derived from donated fat tissue that have been processed and expanded in a laboratory.

The purpose of this research is to evaluate if these cells, when given through intravenous injection, are safe to use and can help heal the skin in patients with SJS-TEN. The treatment involves giving patients a specific dose of these cells based on their body weight. During the study, doctors will monitor how quickly the skin heals and check for any side effects from the treatment.

Participants will receive the cell treatment and will be monitored for several months afterward. The medical team will assess skin healing, particularly in the first week after treatment, and continue to observe the recovery of affected areas including the mouth, nose, eyes, and genital regions. They will also track the overall recovery and any lasting effects of the condition for up to one year after treatment.

]]> Study on Filgrastim for Patients with Severe Bullous Drug Eruptions: Lyell and Stevens-Johnson Syndromes https://clinicaltrials.eu/trial/study-on-filgrastim-for-patients-with-severe-bullous-drug-eruptions-lyell-and-stevens-johnson-syndromes/ Wed, 29 Apr 2026 15:00:47 +0000 https://clinicaltrials.eu/trial/study-on-filgrastim-for-patients-with-severe-bullous-drug-eruptions-lyell-and-stevens-johnson-syndromes/ This clinical trial is focused on studying the effects of a medication called filgrastim in treating severe skin reactions known as Stevens-Johnson syndrome and Lyell syndrome. These conditions can cause painful skin rashes and blisters, and in severe cases, can lead to large areas of skin peeling off. The study aims to see if adding filgrastim to the usual treatment can help stop the progression of these skin conditions more effectively than the usual treatment alone.

Participants in the study will be divided into two groups. One group will receive the standard treatment for these skin conditions along with filgrastim, while the other group will receive the standard treatment with a placebo. The study will last for a period of five days, during which the main focus will be on whether the skin condition stops getting worse. The study will also look at other factors, such as how quickly the skin heals, the overall health of participants after 30 days and one year, and any side effects experienced during the study.

The medication filgrastim is given as an injection or infusion, which means it is administered directly into the body through a needle. Another substance used in the study is glucose monohydrate, which is a type of sugar solution often used in medical treatments. The goal of the study is to determine if filgrastim can provide additional benefits in treating these severe skin conditions, potentially improving recovery and quality of life for those affected.

]]>